Stakeholders want FDA to address alternatives, sample retention in biopsy guidance
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)